Sibeprenlimab (VOYXACT): The First APRIL-Targeted Antibody Approved for IgA Nephropathy (September 10, 2026)
Table of Contents
- One antibody against a single kidney-damaging signal
- What goes wrong in IgA nephropathy
- How sibeprenlimab works
- The VISIONARY Phase 3 trial
- Where it came from: ENVISION and the Otsuka/Visterra story
- FDA accelerated approval
- How it compares with other IgAN therapies
- Safety, cautions and the road ahead
One antibody against a single kidney-damaging signal
Sibeprenlimab, sold as VOYXACT (nonproprietary name sibeprenlimab-szsi, development code VIS649), is a humanized monoclonal antibody built to switch off one specific immune signal that drives IgA nephropathy: a cytokine called APRIL, short for 'a proliferation-inducing ligand.' APRIL and its close relative BAFF keep antibody-producing B cells and plasma cells alive and active. In IgA nephropathy (IgAN), that antibody machinery goes wrong in a very particular way - and sibeprenlimab is the first therapy approved specifically to interrupt it. Rather than broadly suppressing the immune system, the antibody binds free APRIL with extraordinary tightness (a reported dissociation constant of about 0.95 picomolar) and holds onto it, so APRIL can no longer reach its receptors on B cells. That single, upstream intervention turns out to be enough to change the course of the disease.
What goes wrong in IgA nephropathy
IgA nephropathy is one of the most common causes of primary glomerular disease worldwide and a frequent path to kidney failure in young adults. The problem starts with a mis-made antibody. Under the influence of APRIL, certain B cells overproduce a defective form of immunoglobulin A called galactose-deficient IgA1, or Gd-IgA1 - IgA1 that is missing sugar groups it should normally carry. The immune system treats this abnormal IgA1 as foreign and makes antibodies against it, and the two stick together into immune complexes. Those complexes lodge in the glomeruli, the kidney's tiny filtering units, where they trigger inflammation and scarring. The visible result is protein leaking into the urine (proteinuria) and, over years, a steady decline in the kidney's filtering capacity, measured as estimated glomerular filtration rate (eGFR). Because APRIL sits near the very top of this chain - driving the B cells that make Gd-IgA1 in the first place - neutralizing it is one of the most direct ways to attack the disease at its source.
How sibeprenlimab works
Sibeprenlimab is a humanized IgG2 antibody that acts as a high-affinity trap for APRIL. By binding circulating APRIL, it prevents the cytokine from signaling through its receptors TACI and BCMA on B cells and plasma cells. Downstream, that lowers the production of Gd-IgA1 and of the autoantibodies against it, so fewer kidney-damaging immune complexes form and reach the glomeruli. In clinical studies, this shows up as falling levels of serum Gd-IgA1, APRIL and the immunoglobulins IgA, IgG and IgM - a molecular fingerprint confirming the drug is doing exactly what it was designed to do. Because sibeprenlimab is a full-length antibody with a long half-life, it can be given as a fixed 400 mg dose injected under the skin once every four weeks, from a single-dose prefilled syringe that patients or caregivers can use at home after training.
The VISIONARY Phase 3 trial
Sibeprenlimab's pivotal evidence comes from VISIONARY (NCT05248646), a randomized, double-blind, placebo-controlled study that is the largest Phase 3 trial ever conducted in IgA nephropathy. Adults with biopsy-confirmed IgAN at risk of progression received either sibeprenlimab or placebo on top of optimized standard supportive care, with the reduction in 24-hour urine protein-to-creatinine ratio (uPCR) as the primary endpoint. In the prespecified interim analysis, sibeprenlimab delivered a statistically significant and clinically meaningful reduction in proteinuria - about a 51% placebo-adjusted reduction at nine months, deepening to roughly 54% at twelve months. Just as important, an interim analysis of kidney function suggested eGFR was essentially preserved: patients on sibeprenlimab held roughly steady (a mean change of about +0.7 mL/min/1.73 m2 over 12 months) while the placebo group declined by about 4.8 mL/min/1.73 m2. The interim results were published in the New England Journal of Medicine and presented at the American Society of Nephrology's Kidney Week.
Where it came from: ENVISION and the Otsuka/Visterra story
The molecule was discovered by Visterra, a biotech Otsuka Pharmaceutical acquired in 2018, and carried the code VIS649. It first proved itself in the Phase 2 ENVISION trial (NCT04287985), a dose-ranging study in which patients received 2, 4 or 8 mg/kg of sibeprenlimab or placebo. At twelve months, the three doses reduced proteinuria by roughly 47%, 59% and 62% respectively, compared with about 20% for placebo - a clean dose-response that justified moving to the pivotal Phase 3 program. Those complete Phase 2 results were also published in the New England Journal of Medicine, an unusual double for a single compound and a sign of how much interest the APRIL hypothesis had generated in nephrology.
FDA accelerated approval
On the strength of the VISIONARY interim data, an FDA Breakthrough Therapy Designation and a Priority Review of its Biologics License Application, VOYXACT received FDA accelerated approval in November 2025 to reduce proteinuria in adults with primary IgA nephropathy who are at risk of disease progression. Accelerated approval is granted on the basis of a surrogate endpoint - here, the reduction in proteinuria - that is reasonably likely to predict clinical benefit, with continued approval potentially contingent on confirming that benefit in longer-term data. Otsuka began a rolling supplemental filing in 2026 seeking traditional approval supported by the trial's 24-month kidney-function (eGFR) endpoint, which would move the drug from 'lowers a biomarker' to 'demonstrably protects the kidney' in regulatory terms.
How it compares with other IgAN therapies
Sibeprenlimab arrives amid a burst of innovation in IgA nephropathy, and its distinguishing feature is precision. It is a monoclonal antibody that targets APRIL alone, placing it in the same mechanistic family as the APRIL antibody zigakibart. That contrasts with the dual BAFF/APRIL inhibitors - engineered decoy-fusion proteins such as povetacicept (ALPN-303) and telitacicept - which soak up both cytokines at once with an engineered TACI domain fused to an antibody Fc. Other approaches attack different points in the disease: endothelin and complement inhibitors, sparsentan (a dual endothelin/angiotensin blocker), and targeted-release budesonide. The open scientific question is whether blocking APRIL by itself is as durable and protective as blocking both APRIL and BAFF - a comparison the field will be watching for years. Whatever the answer, sibeprenlimab is the proof of concept that made APRIL a validated target, and the first to reach patients with a specific IgAN label.
Safety, cautions and the road ahead
Because sibeprenlimab dampens antibody production, its safety profile centers on the immune system: serum immunoglobulins fall as a class effect, vaccine responses can be blunted, and susceptibility to infection can rise, so clinicians recommend completing vaccinations before starting where possible and generally avoiding live vaccines during treatment. As with any injected biologic, hypersensitivity and injection-site reactions are possible, and long-term, repeat-dose safety - along with use in pregnancy and breastfeeding - is still being characterized. It is a prescription biologic that must be prescribed and monitored by a specialist, usually a nephrologist, and it is used alongside, not instead of, guideline-recommended supportive care such as renin-angiotensin system blockade and SGLT2 inhibitors. Anything sold as 'sibeprenlimab' or 'VIS649' outside a licensed pharmacy is unverified and should be avoided. For patients with IgA nephropathy, though, the arrival of an APRIL-targeted antibody that cuts proteinuria by half and appears to preserve kidney function marks a genuine turning point for a disease that not long ago had almost no treatments aimed at its root cause. This article is background information, not medical advice.
Ready to track your peptide research?
Open PepTracker ProPepTracker Pro Research Team
The PepTracker Pro Research Team is an editorial group of science writers, pharmacologists, and clinical researchers dedicated to making peptide science accessible. Every article is reviewed for accuracy against peer-reviewed sources and updated as new evidence emerges.
Citations
- [1] Otsuka Receives FDA Accelerated Approval for VOYXACT (sibeprenlimab-szsi) for the Reduction of Proteinuria in Adults with Primary IgA Nephropathy (IgAN) at Risk for Disease Progression - Otsuka US (November 2025) Source
- [2] Sibeprenlimab in IgA Nephropathy - Interim Analysis of a Phase 3 Trial (VISIONARY) - New England Journal of Medicine (2025) Source
- [3] Otsuka Sibeprenlimab Phase 3 (VISIONARY) Data Show a Statistically Significant and Clinically Meaningful Proteinuria Reduction for IgAN - Otsuka US (November 10, 2025) Source
- [4] Otsuka Presents Positive Interim Phase 3 VISIONARY eGFR Data Showing VOYXACT (sibeprenlimab-szsi) Preserved Kidney Function Over 12 Months in IgAN - Otsuka US Source
- [5] Label: VOYXACT (sibeprenlimab-szsi) injection - DailyMed (U.S. National Library of Medicine) Source
- [6] Sibeprenlimab Receives U.S. FDA Breakthrough Therapy Designation for the Treatment of IgA Nephropathy - Otsuka US Source
- [7] Sibeprenlimab-szsi for Primary IgA Nephropathy: A New Drug Review - Pharmacy Times Source
- [8] New England Journal of Medicine Publishes Complete Results of Positive Phase 2 (ENVISION) Trial of Sibeprenlimab in IgAN - Otsuka US Source
Related Articles
Sotatercept (Winrevair): The Activin Trap That Made Pulmonary Arterial Hypertension a Treatable Disease, Not Just a Managed One (July 18, 2026)
Merck's sotatercept (Winrevair) is a fusion protein that traps activin A, activin B, myostatin and GDF-11 - and it changed what pulmonary arterial hypertension therapy can aim for. STELLAR delivered a 40.8-meter gain in 6-minute walk distance; ZENITH cut death, transplant and hospitalization by 76% in the sickest patients and led to an expanded FDA label on October 27, 2025. Here is how the broadest activin-axis drug compares with the selective antibodies chasing the same biology.
Efgartigimod (Vyvgart): The Antibody Fragment That Treats Autoimmune Disease by Deleting Your Own Antibodies (July 23, 2026)
Most autoimmune drugs suppress the whole immune system. Efgartigimod does something narrower and stranger: it blocks the receptor that recycles your antibodies, so your own pathogenic IgG gets thrown out with the trash. In May 2026 the FDA made it the first and only myasthenia gravis drug approved for every antibody serotype.
Rozanolixizumab (Rystiggo): The Subcutaneous FcRn Blocker That Reached Both Myasthenia Serotypes First (July 25, 2026)
Two days after efgartigimod and one after nipocalimab, meet the third FcRn blocker. Rozanolixizumab uses the same trick - stop the receptor that recycles your antibodies - but delivered under the skin, in cycles, and it was the first drug approved to cover both the AChR- and MuSK-antibody myasthenia serotypes. It's also an honest lesson in the mechanism's limits: it failed in CIDP.
Povetacicept (ALPN-303): A Dual BAFF/APRIL Fusion Protein Nears Approval for IgA Nephropathy (September 9, 2026)
Povetacicept (ALPN-303) is an investigational once-monthly fusion protein that blocks both BAFF and APRIL, the cytokines that keep antibody-producing B cells alive. Built from an engineered TACI decoy fused to an antibody Fc, it targets the B-cell driver of IgA nephropathy. A positive Phase 3 RAINIER interim analysis and an FDA accelerated-approval filing (PDUFA November 30, 2026) have made it one of the most closely watched biologics in nephrology.